Company: BDRX
Filing Date: 2025-11-03
Form Type: 424B3
Source: 0001214659-25-015744
Chunk: 5

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-03
Form: 424B3
Chunk 5
---
 been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is
activated during tumorigenesis.

Tolimidone is an orally delivered, potent and
selective inhibitor of Lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic
cells, in neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycaemic control via insulin sensitization in animal models
of diabetes and has the potential to become a first in class blood glucose modulating agent.

MTX110 is a solubilized formulation of the histone
deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery
(CED) at chemotherapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and potentially avoiding systemic
toxicity.

Biodexa is supported by three proprietary drug
delivery technologies focused on improving the bio-delivery and bio-distribution of medicines. Biodexa’s headquarters and R&D
facility is in Cardiff, UK. For more information visit www.biodexapharma.com.

Forward-Looking Statements

Certain statements in this announcement may constitute
“forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States. Such statements
are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on management’s
belief or interpretation. All statements contained in this announcement that do not relate to matters of historical fact should be considered
forward-looking statements. In certain cases, forward-looking statements can be identified by the use of words such as “plans”,
“expects” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements
that certain actions, events or results “may”, “could”, “would”, “might” or “will
be taken”, “occur” or “be achieved.” Forward-looking statements and information are subject to various known
and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual
results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions
about such risks, uncertainties and other factors set out herein.

Reference should be made to those documents that
Biodexa